Latest Trials

EudraCT Number: 2018-003323-10

Sponsor Protocol Number: V712-305(EPOPEX)

Start Date:

Sponsor Name: DBV TECHNOLOGIES S.A.

Full Title: EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX)

Medical condition: Peanut allergy

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	100000004870	10034202	Peanut allergy	LLT

Population Age: Infants and toddlers, Children, Under 18

Gender: Male, Female

Trial protocol: IE (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Ongoing) FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-004734-11

Sponsor Protocol Number: J1S-MC-JP04

Start Date:

Sponsor Name: Eli Lilly and Company

Full Title: A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing's Sarcoma

Medical condition: Ewing's Sarcoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10015560	Ewing's sarcoma	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2009-015988-13

Sponsor Protocol Number: REC15/2375-IT-CL0336

Start Date:

Sponsor Name: Recordati S.p.A.,

Full Title: An international multicentre, randomized, parallel group, double-blind trial to evaluate different dose combinations of lercanidipine and enalapril in comparison with each component administered al...

Medical condition: Essential hypertension

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.0		10015488	Essential hypertension	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) ES (Completed) FR (Completed) PL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2015-003314-24

Sponsor Protocol Number: CC-10004-PPSO-001

Start Date:

Sponsor Name: Celgene Corporation

Full Title: A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis

Medical condition: Moderate to severe plaque psoriasis in adolescents (ages 12 to 17 years, inclusive) and in children (ages 6 to 11 years, inclusive).

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.1	10040785 - Skin and subcutaneous tissue disorders	10071117	Plaque psoriasis	LLT
	18.1	10040785 - Skin and subcutaneous tissue disorders	10037153	Psoriasis	PT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (Completed) DE (Completed) ES (Completed) Outside EU/EEA

Trial results: View results

EudraCT Number: 2006-001491-21

Sponsor Protocol Number: 1-2006

Start Date:

Sponsor Name: Max Planck Institute of Psychiatry

Full Title: Studies on Permeability of the Blood-Brain-Barrier for Escitaloprame related to various Genotypes of the ABCB1-Gene: Effects on Sleep and Motoric Learning

Medical condition: Effects on sleep electroencephalogram and motoric learning in healthy volunteers related to the permeability of the blood-brain-barrier related to genotypes of the ABCB 1 gene

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults

Gender: Male

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-004167-27

Sponsor Protocol Number: RM-493-033

Start Date:

Sponsor Name: Rhythm Pharmaceuticals Limited

Full Title: A Phase 3 Multi-Center, One-Year, Open-Label study of Setmelanotide in Pediatric Patients Aged 2 to

Medical condition: POMC deficiency obesity due to mutations in the POMC gene PCSK1 deficiency due to mutations in the PCSK1 gene LEPR deficiency obesity due to mutations in the LEPR gene Bardet-Biedl syndrome

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.0	10010331 - Congenital, familial and genetic disorders	10084105	Leptin receptor deficiency	PT
	23.0	10010331 - Congenital, familial and genetic disorders	10083937	Pro-opiomelanocortin deficiency	PT
	20.1	10010331 - Congenital, familial and genetic disorders	10048680	Bardet-Biedl syndrome	LLT

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2018-001571-21

Sponsor Protocol Number: P18.037

Start Date:

Sponsor Name: Leiden University

Full Title: Training immune functions through pharmacotherapeutic conditioning in juvenile idiopathic arthritis

Medical condition: Juvenile Idiopathic Arthritis

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-002858-24

Sponsor Protocol Number: D-CA-60130-452

Start Date:

Sponsor Name: Clementia Pharmaceuticals Inc, an Ipsen Company

Full Title: A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of 2 dosage regimens of oral IPN60130 for the treatment of fibrodysplasia ossificans pr...

Medical condition: fibrodysplasia ossificans progressiva (FOP)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10068715	Fibrodysplasia ossificans progressiva	PT

Population Age: Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) SE (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) BE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2013-005429-21

Sponsor Protocol Number: OPTIMIST-Aprotocol

Start Date:

Sponsor Name: Menzies Research Institute Tasmania

Full Title: Multicentre randomised controlled trial of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation on continuous positive airway pressure (CPAP)

Medical condition: Infant respiratory distress syndrome, also known as hyaline membrane disease.

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	100000004855	10020477	Hyaline membrane disease	LLT

Population Age: In utero, Preterm newborn infants, Under 18

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA SI (Ongoing) NL ()

Trial results: (No results available)

EudraCT Number: 2008-008689-11

Sponsor Protocol Number: 3/15.12.2008

Start Date:

Sponsor Name: Children's Memorial Health Institute

Full Title: Efficacy and safety of omega – 3 based lipid solution (Omegaven) in comparison with Lipofundin LCT/MCT in reducing cholestasis in children on parenteral nutrition – randomized double – blind clinic...

Medical condition: Parenteral nutrition associated liver disease (PNALD) MedDRA LLT: total parenteral nutrition MedDRA PT: parenteral nutrition MedDRA LLT: liver cholestasis MedDRA PT: cholestasis

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: PL (Prematurely Ended)

Trial results: (No results available)

Latest Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions